Apolipoprotein E: A Potent Gene-Based Therapeutic Target for the Treatment of Sporadic Alzheimer's Disease

  • Judes Poirier

Alzheimer’s disease (AD) is associated with neuronal loss, synaptic damage, deposition of β-amyloid, and loss of cholinergic activity in susceptible brain regions. The latter three neuropathological markers of AD were shown to be markedly modulated by the presence of the apolipoprotein E4 (apoE4) allele in sporadic AD subjects. The apoE4 allele is a well-known risk factor for both sporadic and familial late-onset AD. It was shown that patients with two E4 alleles exhibit an earlier age of onset (Corder et al., 1993; Poirier et al., 1993), higher amyloid plaque counts (Rebeck, Reiter, Strickland, & Hyman, 1993; Schmechel et al., 1993), cerebrovascular amyloid deposition (Schmechel et al., 1993), and marked reductions in choline acetyltransferase (Allen et al., 1997; Arendt et al., 1997; Poirier, Delisle, et al., 1995), and nicotinic and nerve growth factor receptors (Arendt et al., 1997) density compared with non-E4 allele subjects.


Clinical Dementia Rating apoE Level Mild Cognitively Impaired Subject apoE4 Carrier apoE Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aleong, R., Aumont, N., Dea, D., & Poirier, J. (2003). Non-steroidal anti-inflammatory drugs mediate increased in vitro glial expression of apolipoprotein E protein. European Journal of Neuroscience, 18, 1428–1438.CrossRefPubMedGoogle Scholar
  2. Allen, S. J., MacGowan, S. H., Tyler, S., Wilcock, G. K., Robertson, A. G., Holden, P. H., et al. (1997). Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein E4 genotype. Neuroscience Letters, 239, 33–36.CrossRefPubMedGoogle Scholar
  3. Arendt, T, Schindler, C., Bruckner, M. K., Eschrich, K., Bigl, V., Zedlick, D., et al. (1997). Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. The Journal of Neuroscience, 17, 516–529.PubMedGoogle Scholar
  4. Beffert, U., Aumont, N., Dea, D., Lussier-Cacan, S., Davignon, J., & Poirier, J. (1999). Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures. Brain Research. Molecular Brain Research, 68, 181–185.CrossRefPubMedGoogle Scholar
  5. Beffert, U., & Poirier, J. (1996). Apolipoprotein E, plaques, tangles and cholinergic dysfunction in Alzheimer's disease. Neurobiology of Alzheimer's Disease, 777, 166–174.Google Scholar
  6. Bertrand, P., Poirier, J., Oda, T., Finch, C. E., & Pasinetti, G. M. (1995). Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Brain Research. Molecular Brain Research, 33, 174–178.CrossRefPubMedGoogle Scholar
  7. Buttini, M., Orth, M., Bellosta, S., Akeefe, H., Pitas, R.E., Wyss-Coray, T., et al. (1999). Expression of human apolipoprotein E3 or E4 in the brains of apoE -/- mice: Isoform-specific effects on neurodegeneration. The Journal of Neuroscience, 19, 4867–4880.PubMedGoogle Scholar
  8. Champagne, D., Dupuy, J. B., Rochford, J., & Poirier, J. (2002). Apolipoprotein E knockout mice display procedural deficits in the Morris water maze: Analysis of learning strategies in three versions of the task. Neuroscience, 114, 641–654.CrossRefPubMedGoogle Scholar
  9. Champagne, D., Rochford, J., & Poirier, J. (2005). Effect of apolipoprotein E deficiency on reactive sprouting in the dentate gyrus of the hippocampus following entorhinal cortex lesion: Role of the astroglial response. Experimental Neurology, 194, 31–42.CrossRefPubMedGoogle Scholar
  10. Chapman, S., Sabo, T., Roses, A. D., & Michaelson, D. M. (2000). Reversal of presynaptic deficits of apolipoprotein E-deficient mice in human apolipoprotein E transgenic mice. Neuroscience, 97, 419–424.CrossRefPubMedGoogle Scholar
  11. Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C. J., et al. M. A. (1994). Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genetics, 7, 180–184.CrossRefPubMedGoogle Scholar
  12. Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., et al. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 261, 921–923.CrossRefPubMedGoogle Scholar
  13. De Leon, M. J., Convit, A., Wolf, O. T., Tarshish, C. Y., DeSanti, S., Rusinek, et al. (2001). Prediction of cognitive decline in normal elderly subjects with 2-[F-18]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proceedings of National Academy of Sciences of the United States of America, 98, 10966–10971.CrossRefGoogle Scholar
  14. Farlow, M. R., He, Y., Tekin, S., Xu, J., Lane, R., & Charles, H. C. (2004). Impact of APOE in mild cognitive impairment. Neurology, 63, 1898–1901.PubMedGoogle Scholar
  15. Finch, C. E., & Stanford, C. B. (2004). Meat-adaptive genes and the evolution of slower aging in humans. The Quarterly Review of Biology, 79, 3–50.CrossRefPubMedGoogle Scholar
  16. Gold, M., Franke, S., Nye, J. S., Goldstein, H. R., Fijal, B., & Cohen, N. (2004). Impact of ApoE genotype on the efficacy of Galantamine for the treatment of mild cognitive impairment. Neurobiology of Aging, 24, 521.CrossRefGoogle Scholar
  17. Grootendorst, J., Bour, A., Vogel, E., Kelche, C., Sullivan, P. M., Dodart, J. C., et al. (2005). Human apoE targeted replacement mouse lines: h-apoE4 and h-apoE3 mice differ on spatial memory performance and avoidance behavior. Behavioural Brain Research, 159, 1–14.CrossRefPubMedGoogle Scholar
  18. Holtzman, D. M., Bales, K. R., Wu, S., Bhat, P., Parsadanian, M., Fagan, A. M., et al. (1999). Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. The Journal of Clinical Investigation, 103, R15–R21.CrossRefPubMedGoogle Scholar
  19. MacGowan, S. H., Wilcock, G. K., & Scott, M. (1998). Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease. International Journal of Geriatric Psychiatry, 13, 625–630.CrossRefPubMedGoogle Scholar
  20. Masliah, E., Mallory, M., Ge, N., Alford, M., Veinbergs, I., & Roses, A. D. (1995). Neurodegeneration in the central nervous system of apoE-deficient mice. Experimental Neurology, 136, 107–122.CrossRefPubMedGoogle Scholar
  21. Nathan, B. P., Bellosta, S., Sanan, D. A., Weisgraber, K. H., Mahley, R.W., & Pitas, R. E. (1994). Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science, 264, 850–852.CrossRefPubMedGoogle Scholar
  22. Oddoze, C., Michel, B. F., & Lucotte, G. (2000). Apolipoprotein E epsilon 4 allele predicts a better response to donepezil therapy in Alzheimer's disease. Alzheimers Reports, 3, 213–216.Google Scholar
  23. Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., et al. (2005). Vitamin E and donepezil for the treatment of mild cognitive impairment. The New England Journal of Medicine, 352, 2379–2388.CrossRefPubMedGoogle Scholar
  24. Poirier, J. (1994). Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends in Neurosciences, 17, 525–530.CrossRefPubMedGoogle Scholar
  25. Poirier, J. (2003). Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends in Molecular Medicine, 9, 94–101.CrossRefPubMedGoogle Scholar
  26. Poirier, J. (2005). Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiology of Aging, 26, 355–361.CrossRefPubMedGoogle Scholar
  27. Poirier, J., Davignon, J., Bouthillier, D., Kogan, S., Bertrand, P., & Gauthier, S. (1993). Apolipoprotein E polymorphism and Alzheimer's disease. Lancet, 342, 697–699.CrossRefPubMedGoogle Scholar
  28. Poirier, J., Delisle, M. C., Quirion, R., Aubert, I., Farlow, M., Lahiri, D., et al. (1995). Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proceedings of National Academy of Sciences of the United States of America, 92, 12260–12264.CrossRefGoogle Scholar
  29. Poirier, J., Minnich, A., & Davignon, J. (1995). Apolipoprotein E, synaptic plasticity and Alzheimer's disease. Annals of Medicine, 27, 663–670.CrossRefPubMedGoogle Scholar
  30. Poirier, J., & Panisset, M. (2002). Apolipoprotein E: A novel therapeutic target for the treatment of Alzheimer's Disease. Advances in Experimental Medicine and Biology, 36–42.Google Scholar
  31. Rebeck, G. W., Reiter, J. S., Strickland, D. K., & Hyman, B. T. (1993). Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions. Neuron, 11, 575–580.CrossRefPubMedGoogle Scholar
  32. Richard, F., Helbecque, N., Neuman, E., Guez, D., Levy, R., & Amouyel, P. (1997). APOE genotyping and response to drug treatment in Alzheimer's disease. Lancet, 349, 539.CrossRefPubMedGoogle Scholar
  33. Risner, M. E., Saunders, A. M., Altman, J. F., Ormandy, G. C., Craft, S., Foley, I. M., et al. (2006). Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. The Pharmacogenomics Journal, 6, 246–254.PubMedGoogle Scholar
  34. Rogers, J., Kirby, L. C., Hempelman, S. R., Berry, D. L., McGeer, P. L., Kaszniak, A. W., et al. (1993). Clinical trial of indomethacin in Alzheimer's disease. Neurology, 43, 1609–1611.PubMedGoogle Scholar
  35. Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., et al. (1993). Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proceedings of National Academy of Sciences of the United States of America, 90, 9649–9653.CrossRefGoogle Scholar
  36. Stone, D. J., Rozovsky, I., Morgan, T. E., Anderson, C. P., & Finch, C. E. (1998). Increased synaptic sprouting in response to estrogen via an apolipoprotein E-dependent mechanism: Implications for Alzheimer's disease. The Journal of Neuroscience, 18, 3180–3185.PubMedGoogle Scholar
  37. Strittmatter, W. J., Saunders, A. M., Goedert, M., Weisgraber, K. H., Dong, L. M., Jakes, R., et al. (1994). Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: Implications for Alzheimer disease. Proceedings of National Academy of Sciences of the United States of America, 91, 11183–11186.CrossRefGoogle Scholar
  38. Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., et al. (1993). Binding of human apolipoprotein E to synthetic amyloid beta peptide: Isoform-specific effects and implications for late-onset Alzheimer disease. Proceedings of National Academy of Sciences of the United States of America, 90, 8098–8102.CrossRefGoogle Scholar
  39. Tolar, M., Marques, M. A., Harmony, J. A., & Crutcher, K. A. (1997). Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated. The Journal of Neuroscience, 17, 5678–5686.PubMedGoogle Scholar
  40. Utermann, G., Langenbeck, U., Beisiegel, U., & Weber, W. (1980). Genetics of the apolipoprotein E system in man. American Journal of Human Genetics, 32, 339–347.PubMedGoogle Scholar
  41. Veinbergs, I., Mante, M., Jung, M. W., Van Uden, E., & Masliah, E. (1999). Synaptotagmin and synaptic transmission alterations in apolipoprotein E-deficient mice. Progress in Neuro-Psychopharmacology are Biological Psychiatry, 23, 519–531.CrossRefGoogle Scholar
  42. Veinbergs, I., & Masliah, E. (1999). Synaptic alterations in apolipoprotein E knockout mice. Neuroscience, 91, 401–403.CrossRefPubMedGoogle Scholar
  43. Yue, L., Rasouli, N., Ranganathan, G., Kern, P. A., & Mazzone, T. (2004). Divergent effects of peroxisome proliferator-activated receptor gamma agonists and tumor necrosis factor alpha on adipocyte ApoE expression. The Journal of Biological Chemistry, 279, 47626–47632.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Judes Poirier
    • 1
  1. 1.McGill Centre for Studies in Aging and Douglas Hospital Research CentreMontrealCanada

Personalised recommendations